Literature DB >> 24997557

Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

J P Sharman1, J Chmielecki2, D Morosini2, G A Palmer2, J S Ross3, P J Stephens2, J Stafl4, V A Miller2, S M Ali2.   

Abstract

Entities:  

Keywords:  Mitogen-activated protein kinase; Mutation; Refractory myeloma; V600E; Vemurafenib

Mesh：

Substances：

Year:  2014        PMID： 24997557     DOI： 10.1016/j.clml.2014.06.004

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  19 in total

Review 1.  Gene Expression Profiles in Myeloma: Ready for the Real World?

Authors:  Raphael Szalat; Herve Avet-Loiseau; Nikhil C Munshi
Journal:  Clin Cancer Res       Date:  2016-11-15       Impact factor: 12.531

Review 2.  Toward personalized treatment in multiple myeloma based on molecular characteristics.

Authors:  Charlotte Pawlyn; Faith E Davies
Journal:  Blood       Date:  2018-12-26       Impact factor: 22.113

3.  Genetic interrogation of circulating multiple myeloma cells at single-cell resolution.

Authors:  Jens G Lohr; Sora Kim; Joshua Gould; Birgit Knoechel; Yotam Drier; Matthew J Cotton; Daniel Gray; Nicole Birrer; Bang Wong; Gavin Ha; Cheng-Zhong Zhang; Guangwu Guo; Matthew Meyerson; Andrew J Yee; Jesse S Boehm; Noopur Raje; Todd R Golub
Journal:  Sci Transl Med       Date:  2016-11-02       Impact factor: 17.956

4.  BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.

Authors:  Svetlana A Protsenko; Anna I Semionova; Yuri I Komarov; Svetlana N Aleksakhina; Alexandr O Ivantsov; Aglaya G Iyevleva; Evgeny N Imyanitov
Journal:  Invest New Drugs       Date:  2015-08-20       Impact factor: 3.850

5.  Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.

Authors:  Fazal Shirazi; Richard J Jones; Ram K Singh; Jianxuan Zou; Isere Kuiatse; Zuzana Berkova; Hua Wang; Hans C Lee; Samuel Hong; Larry Dick; Nibedita Chattopadhyay; Robert Z Orlowski
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-03       Impact factor: 11.205

6.  Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.

Authors:  E Müller; S Bauer; T Stühmer; A Mottok; C-J Scholz; T Steinbrunn; D Brünnert; A Brandl; H Schraud; S Kreßmann; A Beilhack; A Rosenwald; R C Bargou; M Chatterjee
Journal:  Leukemia       Date:  2016-09-30       Impact factor: 11.528

Review 7.  Risk Stratification in Multiple Myeloma.

Authors:  Melissa Gaik-Ming Ooi; Sanjay de Mel; Wee Joo Chng
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

Review 8.  A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration.

Authors:  Christian M Schürch; Leo Rasche; Leonie Frauenfeld; Niels Weinhold; Falko Fend
Journal:  Virchows Arch       Date:  2019-12-17       Impact factor: 4.064

9.  BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.

Authors:  E H Rustad; H Y Dai; H Hov; E Coward; V Beisvag; O Myklebost; E Hovig; S Nakken; D Vodák; L A Meza-Zepeda; A K Sandvik; K F Wader; K Misund; A Sundan; H Aarset; A Waage
Journal:  Blood Cancer J       Date:  2015-03-20       Impact factor: 11.037

10.  Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.

Authors:  Rikio Suzuki; Shohei Kikuchi; Takeshi Harada; Naoya Mimura; Jiro Minami; Hiroto Ohguchi; Yasuhiro Yoshida; Morihiko Sagawa; Gullu Gorgun; Diana Cirstea; Francesca Cottini; Jana Jakubikova; Yu-Tzu Tai; Dharminder Chauhan; Paul G Richardson; Nikhil Munshi; Kiyoshi Ando; Teruhiro Utsugi; Teru Hideshima; Kenneth C Anderson
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.